The roof is one of the most expensive components of a commercial or industrial property. It protects everything inside yet, ...

Preliminary unaudited Q4 and Full Year 2025 net Attruby®product revenue of $146.0 million and $362.4 million, respectively ...

Group calls for review of retailer’s partnership with Flock Safety, whose data has been used in ​immigration enforcement ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

This publication has not been sponsored or paid for by any external entities. The insights and perspectives shared are organic, reflecting the author's genuine viewpoints and professional expertise ...

ARKF offers thematic returns through growth stock exposure, benefiting from pro-risk environments and tech rallies. See why ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Ebony Howard is a certified public accountant and a QuickBooks ProAdvisor tax expert. She ...

A. A mark is a given and known sign by which a thing can be distinguished from all others of its kind. Thus a trademark is used to distinguish the article bearing it from all imitations of the same ...

If you’ve been watching your analytics lately, you might have noticed a confusing trend: organic search numbers are dipping, ...

The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.